FDA Identifies Deficiencies in Anaphylm NDA, Potentially Delaying Approval

summarizeSummary

Aquestive Therapeutics announced that the FDA identified deficiencies in the New Drug Application for its lead product candidate, Anaphylm, which could delay its approval, though the review is ongoing.

check_boxKey Events · Product Development and Regulatory · AQST

• FDA Deficiency Notice for Anaphylm NDA

  The U.S. Food and Drug Administration (FDA) identified deficiencies in the New Drug Application (NDA) for Anaphylm™ (epinephrine) Sublingual Film, precluding discussions on labeling and post-marketing commitments.

• Potential Delay in Approval

  This development could result in a delay of the possible FDA approval for Anaphylm, which has a PDUFA goal date of January 31, 2026.

• Review Remains Ongoing

  The FDA clarified that the notification does not reflect a final decision and its review of the NDA is ongoing, with the company working to understand and resolve the concerns.

• Strong Cash Position

  The company reported approximately $120 million in cash and cash equivalents as of December 31, 2025, stating it has sufficient capital to execute its long-term strategy.

auto_awesomeAnalysis · AQST · Life Sciences

The FDA's notification of deficiencies in the Anaphylm NDA, while not a final decision, signals a significant hurdle for Aquestive Therapeutics. The inability to discuss labeling and post-marketing commitments indicates material issues that need to be resolved. This development introduces uncertainty regarding the PDUFA goal date of January 31, 2026, and could lead to a delay in the potential approval of a key product. Investors should monitor for further details on the specific deficiencies and the company's plan to address them, as the successful approval and launch of Anaphylm are critical to the company's long-term growth strategy.